We're hiring! A great opportunity to work as part of a dynamic and growing team at UNSW. Looking for people with skills using population data to work on NHMRC funded projects investigating hospital and pharmacological cardiovascular care Medicines Intelligence CRE external-careers.jobs.unsw.edu.au/cw/en/job/5069…

Congratulations Juliana! Looking forward to some fantastic research ahead

Great day today! Paper by Andrea Schaffer on multi-medicine use in patients with CVD is out. Not surprisingly it’s very common, check out the visualisations breaking down the combinations used. Also had my 50th paper accepted - celebrate the wins! Medicines Intelligence CRE doi.org/10.1002/phar.2…

Can real-world data address an evidence gap where there are zero RCTs available? So proud of our paper comparing outcomes of different endograft devices for AAA repair. Editors choice! UNSW Centre for Big Data Research in Health Medicines Intelligence CRE doi.org/10.1016/j.ejvs…

For people who want to quit smoking, is varenicline better at reducing repeat heart attacks than nicotine patches? Our study on this question just published: heart.bmj.com/content/early/… Michael Falster Kristian Filion Clara Chow NDARC, UNSW Medicines Intelligence CRE Heart_BMJ

Please join us at 2pm on Tuesday 21st March to hear from our special guest dani prieto-alhambra - "Data stays local - evidence goes global" and what Australia can learn from the DARWIN-EU project. Register micre-prieto.eventbrite.com.au to attend. OHDSI Australia Chapter UNSW Centre for Big Data Research in Health UNSW Medicine & Health

ICYMI, our recent study on the comparative effectiveness of smoking cessation pharmacotherapies for secondary prevention of cardiovascular disease Clara Chow Kristian Filion Sallie Pearson Michael Falster

“Continuous comparative assessments are needed to guide evidence for treatment decisions across the range of available devices” - Michael Falster, Ramon Varcoe & colleagues #endograft #endovascular #aneurysm #EVAR ow.ly/pzu350NuH62

Low persistence to 4 groups of cardiovascular medicines in 3 years, but high adherence while people are on therapy. Cardiovascular multi-medicine use is common (>31%) but does not appear to impair persistence and adherence to therapy. doi.org/10.1161/JAHA.1… Medicines Intelligence CRE

Thrilled to present on the epidemiology of SGLT2i and GLP-1RAs at Australasian Diabetes Congress. Thanks for inviting me - we’ve got some great work ahead!! #ADC2023 Medicines Intelligence CRE UNSW Medicine & Health Sallie Pearson Juliana Costa Jialing Lin

Yes23 campaigner Jade Ritchie joined Narelda Jacobs for a rapid fire question round on the Voice! #yes23

REGISTRATION NOW OPEN: 2023 NSW CVRN EMCR Masterclass. 16 November 9am - 2pm, Lunch provided Register online: forms.office.com/r/W2HXYqiSed

Congratulations Tamie on winning best presentation @ UNSW CVMM Symposium! Endocrinonoloy meets pharmacoepidemiology, ⬆️ SGLT2i & GLP-1RAs as add on therapy for T2D. Thrilled to be part of your work :) UNSW Medicine & Health Medicines Intelligence CRE Juliana Costa Jialing Lin Sallie Pearson

Only a few places left: 2023 NSW CVRN CONSUMER ENGAGEMENT MASTERCLASS. 16 November 9am - 2pm, Lunch provided Register online: forms.office.com/r/W2HXYqiSed

A successful NSW CVRN EMCR Consumer Engagement Masterclass at Uni of Wollongong Business School! Great job to all the working group members! Looking forward to the next meeting or engagement! Now waiting for the final 9th flight back to Melbourne!

Excited to see Medicines Intelligence CRE investigator Jialing Lin present at the NSW CVRN Rising Stars Seminar Series soon. Registrations open!!

Congratulations to Medicines Intelligence CRE researchers on the first study published using the MedIntel Data Platform. They examined how use of highly effective diabetes medicines (SGLT2is and GLP-1RAs) varied across geographic areas of NSW …ubs.pericles-prod.literatumonline.com/doi/10.1111/do… 🧵1/4

Just out! Our review on meds dispensing duration for #hypertension #HypertensionTaskforce The impact of short vs long durations on health costs and outcomes is unknown. Evidence suggests 90-day dispensing could reduce costs and improve adherence nature.com/articles/s4144…